

## The Zyogreen® Difference

The first and only  
**ready-to-use** indocyanine green<sup>[4-7]§</sup>



### Ready-to-Use Solution for Injection

No reconstitution. No extra steps.<sup>[4]</sup>

No diluent vials required and smaller cartons that save space.



### Single-Dose Format

Solution for intravenous or interstitial use,  
supplied as a single-dose ampule.<sup>[4]</sup>



### OR Workflow Efficiency

Fewer preparation steps at point of care can help  
streamline OR workflow.<sup>[1,3]†</sup>



### Fewer Opportunities for Prep Error

Manufacturer-prepared ready-to-use presentations  
have been associated with fewer observed preparation/  
administration errors vs traditional methods.<sup>[1,2]‡</sup>

Scan to learn more.



The first and only **ready-to-use**  
indocyanine green <sup>[4-7]§</sup>



| Product Name                                                                  | Pack Size               | Therapeutic Class | NDC Number   | NDA Number       | Ampule GTIN    |
|-------------------------------------------------------------------------------|-------------------------|-------------------|--------------|------------------|----------------|
| <b>Zyogreen®</b><br>(indocyanine green injection)<br>(25 mg per 10 mL) Ampule | 5 ampules               | Diagnostic Dye    | 25021-841-10 | 218579           | 20325021841109 |
|                                                                               | Wholesaler Item Numbers |                   |              |                  |                |
|                                                                               | Cencora / ABC           | Cardinal          | McKesson     | Morris & Dickson |                |
|                                                                               | 10312547                | 6155691           | 3139201      | 306662           |                |



Scan to learn more.



References:

- Benhamou D, Weiss M, Borms M, et al. Assessing the clinical, economic, and health resource utilization impacts of prefilled syringes versus conventional medication administration methods: results from a systematic literature review. *Ann Pharmacother*. 2024;58(9):921–934. doi:10.1177/10600280231212890.
- Hertig JB, Degnan DD, Scott CR, et al. A Comparison of Error Rates Between Intravenous Push Methods: A Prospective, Multisite, Observational Study. *J Patient Saf*. 2018;14(1):60–65. doi:10.1097/PTS.0000000000000419.
- van der Linden P, Douchamps J, Schmitt C, Forget D. Ready-to-use injection preparations versus conventional reconstituted admixtures: economic evaluation in a real-life setting. *PharmacoEconomics*. 2002;20(8):529–536.
- Zyogreen Prescribing Information. ZYOGREEN®. (indocyanine green injection) solution for intravenous or interstitial use; Dosage Forms and Strengths: ready-to-use solution for injection (25 mg/10 mL) in single-dose ampule; Description: sterile ready-to-use solution for injection. (Revised: 07/2026).
- IC-GREEN™ (Indocyanine Green for Injection, USP). Labeling (NDA 11-525-S-017): sterile, lyophilized green powder packaged with aqueous solvent (sterile water) for dissolution/reconstitution.
- SPY AGENT® GREEN (indocyanine green for injection). Labeling (Revised 06/2023): "For injection: 25 mg ... as a sterile, lyophilized, green powder for reconstitution ...".
- ICG for Injection Set (KARL STORZ Endoscopy-America, Inc.). Labeling (Revised 6/2016): reconstitute 25 mg vial with 10 mL sterile water; sterile, lyophilized green powder.
- Arora P, Muehrcke M, Hertig J. A cost-effectiveness study comparing ready-to-administer and traditional vial-and-syringe method for opioids. *Pain Ther*. 2022;11:937–950. doi:10.1007/s40122-022-00402-z.
- Borms M, Taneja A, Weiss M, et al. Improving efficiency and safety with prefilled syringes: a model-based economic evaluation for US healthcare settings. *ClinicoEconomics Outcomes Res*. 2025;17:673–685. doi:10.2147/CEOR.S544296.

† Outcomes reported in the cited literature vary by workflow, setting and product type; modeled evaluations are assumption-dependent.

‡ Evidence cited describes ready-to-use/ready-to-administer injectable formats broadly and is not specific to Zyogreen or indocyanine green clinical outcomes unless explicitly stated.

§ Substantiation scope note (for “first-and-only” claim): Based on review of available product labeling as of July 2026, including Zyogreen Prescribing Information and comparator ICG product labeling (IC-GREEN™, SPY AGENT® GREEN and ICG for Injection Set [KARL STORZ]). <sup>[4-7]</sup>